COVID-19 Vaccine AstraZeneca (AZD1222; sold as Vaxzevria in Europe)

The COVID-19 Vaccine AstraZeneca (AZD1222; sold as Vaxzevria in Europe) had a 76 percent efficacy against symptomatic SARS-CoV-2 infection. However, this is only applicable to occurrences occurring 15 days after the second dose, with a 29-day inter-dose gap.

Data reveal that two doses of the AstraZeneca vaccine were effective against symptomatic sickness caused by the Delta variant (74.5 percent, CI 68–89 percent) in comparison to the Alpha variant (74.5 percent, CI 68–89 percent). The UK Health Security Agency discovered that Delta had a 71 percent (CI 51–83 percent) effectiveness against hospitalization after one dosage and a 92 percent (CI 75–97 percent) effectiveness after the second dose.

Overall, research demonstrates that the AstraZeneca vaccine is highly effective against the Delta form, particularly in terms of hospitalization.

MORE INFORMATION:
Manufacturer: AstraZeneca Plc.
Number of Shots: 2 shots, 4 to 12 weeks apart
Type of Vaccine: Viral Vector